The Food and Drug Administration says it will begin offering faster reviews to new medicines that align with Trump administration priorities for Americans' health.

The US Food and Drug Administration announced a new national priority voucher plan that aims to cut drug review times to one to two months for companies it says are backing national interests.

FDA Commissioner Marty Makary faces declining staff morale as he remakes the agency.

The FDA is launching a program to reward companies with accelerated drug review and speedy agency feedback, if their actions align with the FDA's national health priorities.

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, others are continuing and pushing regulatory boundaries.

Leaders of the FDA have published a list of new priorities for the agency. They want to deliver rapidly-approved cures and "unleash AI."

A new study from the American Cancer Society’s medical journal found that psilocybin — the active ingredient in “magic mushrooms” — helped with depression